SEC Form 4 · accession 0001437749-15-005863
RESPONSE BIOMEDICAL CORP · RBM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph D Keegan
Director
Period of report
Mar 19, 2015
Accepted (ET)
Mar 23, 2015 · 8:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000806888
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 19, 2015 | A | 6,250 | $0.00 | A | 38,618 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F3 | $0.92 | Mar 19, 2015 | A | 5,000 | A | — | Mar 19, 2025 | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1100% of the restricted share units vested on the date of grant. The expiration date for each of the restricted share units will be the earlier of three (3) years after the effective date or two (2) years following the grantee's termination date. The reporting person has elected to defer receipt of the common stock underlying the restricted share units until a later date not to exceed the expiration date.
- F2Exercise prices shown are denominated in Canadian dollars.
- F3100% of the options vest on March 20, 2016, subject to the reporting person's continued service as a director of the Company through each vesting date.